School of Medicine

The Latest

Patient Shares Gratitude for Life-Saving Lung Cancer Treatment

UC San Diego Health uses a multidisciplinary, comprehensive approach for lung cancer detection, diagnosis and treatment.

Patient David Katz and Mark Onaitis, MD review test results on a computer monitor.

Transforming Medical Education to Save Lives

Future physicians are learning to make their mark with the help of innovative technology that transforms traditional training into a more user-friendly experience. A recent award-winning study is paving the way for this new approach to training medical students in the field of cancer treatment.

Matin Yarmand presents the team's paper at CHI2024.

UC San Diego Ranks 9th in the World for Most Influential Researchers

UC San Diego has the highest number of influential voices in the University of California system and tied for 9th highest among universities and institutes worldwide, according to Clarivate’s 2024 Highly Cited Researchers list.

Collage photos of eight highly cited researchers named in caption.

Preuss Scholars Learn Life-Saving CPR Skills

Over 100 seventh-graders from The Preuss School UC San Diego were trained in hands-only CPR by UC San Diego student volunteers from the Revive & Survive San Diego initiative as part of the school's effort to train all of its scholars.

Researchers Develop Clinically Validated, Wearable Ultrasound Patch for Continuous Blood Pressure Monitoring

A re-engineered wearable ultrasound patch for continuous and noninvasive blood pressure monitoring has undergone comprehensive clinical validation on over 100 patients, marking a major milestone in wearable technology research. The soft, stretchy patch provides precise, real-time readings of blood pressure deep within the body. It could offer a simpler and more reliable alternative to current clinical methods.

Small, transparent square with electronic circuits stuck on the tip of an index finger.

Cetuximab Outperforms Durvalumab in Treatment of Head and Neck Cancers

The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune checkpoint inhibitor.